Neurocrine Biosciences Inc. (NBIX) and Sutro Biopharma Inc. (NASDAQ:STRO) Contrasting side by side

This is therefore a comparing of the dividends, analyst recommendations, institutional ownership, profitability, risk, earnings and valuation in Neurocrine Biosciences Inc. (NASDAQ:NBIX) and Sutro Biopharma Inc. (NASDAQ:STRO). The two are both Biotechnology companies that compete with one another.

Earnings and Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Neurocrine Biosciences Inc. 451.24M 17.36 21.11M 0.18 435.91
Sutro Biopharma Inc. 38.42M 7.02 35.32M -2.21 0.00

Table 1 shows top-line revenue, earnings per share and valuation of the two companies.


Table 2 shows Neurocrine Biosciences Inc. and Sutro Biopharma Inc.’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Neurocrine Biosciences Inc. 4.68% 5.1% 2.4%
Sutro Biopharma Inc. -91.93% 0% 0%


Neurocrine Biosciences Inc. has a Current Ratio of 8.4 and a Quick Ratio of 8.2. Competitively, Sutro Biopharma Inc.’s Current Ratio is 3.5 and has 3.5 Quick Ratio. Neurocrine Biosciences Inc.’s better ability to pay short and long-term obligations than Sutro Biopharma Inc.

Analyst Ratings

The table given features the ratings and recommendations for Neurocrine Biosciences Inc. and Sutro Biopharma Inc.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Neurocrine Biosciences Inc. 0 3 6 2.67
Sutro Biopharma Inc. 0 0 0 0.00

Neurocrine Biosciences Inc. has a consensus price target of $108.75, and a 26.10% upside potential.

Institutional and Insider Ownership

Institutional investors owned 0% of Neurocrine Biosciences Inc. shares and 75.3% of Sutro Biopharma Inc. shares. 1.2% are Neurocrine Biosciences Inc.’s share owned by insiders. Comparatively, insiders own roughly 8.5% of Sutro Biopharma Inc.’s shares.


In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Neurocrine Biosciences Inc. -2.53% -10.56% -11.62% -35.15% -6.23% 10.49%
Sutro Biopharma Inc. -9.77% -14.46% -12.05% 0% 0% 0.33%

For the past year Neurocrine Biosciences Inc. was more bullish than Sutro Biopharma Inc.


Neurocrine Biosciences Inc. beats Sutro Biopharma Inc. on 12 of the 12 factors.

Neurocrine Biosciences, Inc. discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the United States and internationally. The company’s lead products include INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor (VMAT2) used for the treatment of movement disorders; elagolix, a gonadotropin-releasing hormone (GnRH) antagonist that is in Phase III clinical trials used for women’s health; and opicapone, a catechol-O-methyltransferase inhibitor, which is in Phase III clinical trials used for in adjunct therapy and preparations of levodopa/DOPA decarboxylase inhibitors for adult patients with Parkinson’s disease. It is also developing NBI-640756 that is in Phase I clinical trials used for the treatment of essential tremor; and NBI-74788, which is in Phase I clinical trials used for the treatment of classic congenital adrenal hyperplasia. In addition, the company’s research programs comprise VMAT2 Inhibitors for movement disorders, bipolar disorders, and schizophrenia; and G Protein-Coupled Receptors and Ion Channels for epilepsy, essential tremor, pain, and other Indications. It has collaborations with AbbVie Inc. to develop and commercialize elagolix and GnRH antagonists for women’s and men’s health; Mitsubishi Tanabe Pharma Corporation to develop and commercialize INGREZZA for movement disorders; and BIAL – Portela & Ca, S.A. to develop and commercialize opicapone for the treatment of human diseases and conditions, including Parkinson’s disease. Neurocrine Biosciences, Inc. was founded in 1992 and is headquartered in San Diego, California.

Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis platform, XpressCF. The company's product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for multiple myeloma and non-Hodgkin lymphoma; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers. It has collaboration and license agreement with Celgene Corporation to discover and develop bispecific antibodies and/or ADCs focused primarily on the field of immuno-oncology. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.